Esperovax
PrivateLast Round
Grant
Dec 12, 2024
Total Funding Raised
$3.41M
Company Overview
Esperovax operates in Healthcare & Life Sciences and is based in Plymouth, Michigan. Its latest recorded funding round was a Grant round in December 2024.
Esperovax is a biotechnology company that has developed a novel mRNA oral vaccine platform to enable large-scale production and distribution of shelf-stable vaccines.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Defense Tech
Business Model
B2G
Customer Profile
Government Contracts, Revenue Share, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Esperovax Comparables
Compare Esperovax with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Fzata, Inc. | 82% | |
| iosBio | 79% | |
| GIVAX | 75% |
For institutional investors. Book with your work email.
Esperovax Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Dec 12, 2024 | ||||
| Grant | Aug 23, 2023 | ||||
| Seed | Apr 29, 2021 | ||||
| Convertible Debt | Apr 9, 2021 | ||||
| Convertible Debt | Jan 19, 2021 | ||||
Grant | Sep 23, 2020 |
For institutional investors. Book with your work email.
Esperovax Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Northern Michigan Angels | Seed |
| Public Health Emergency Medical Countermeasures Enterprise | Grant |
| Michigan Rise | Convertible Debt, Seed |
| Michigan Strategic Fund | Convertible Debt |
| Johnson & Johnson Innovation - JLABS | Grant |
| Defense Threat Reduction Agency | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 24, 2026
Monthly visitors grew 80% MoM, from 670 to 1.2K.
- May 1, 2025
Monthly visitors increased 907% to 1.4K.
For institutional investors. Book with your work email.
Esperovax Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Esperovax's valuation, stock price, and market status.
Is Esperovax a public or private company?
Esperovax is a private company.
What is the current stock price of Esperovax?
Esperovax is a private company, so its shares have no public market price. Caplight tracks Esperovax's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Esperovax worth (valuation)?
Valuation information for Esperovax is not publicly available.
Can I buy Esperovax stock?
Esperovax shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Esperovax's last funding round?
Esperovax's most recent funding round was Grant on December 12, 2024.
Who are the main investors in Esperovax?
Key investors in Esperovax include Northern Michigan Angels, Public Health Emergency Medical Countermeasures Enterprise, Michigan Rise, Michigan Strategic Fund, Johnson & Johnson Innovation - JLABS.
Will Esperovax IPO soon?
No public IPO plans have been announced for Esperovax.
How can I track Esperovax secondary market activity?
Caplight tracks bids, offers, and trades in Esperovax's shares on secondary markets.